Top Institutional Investors

HighVista Strategies LLC — 13F Holdings & Portfolio

CIK 1335325 · latest 13F-HR filed 2026-08-14

Backtest portfolio

HighVista Strategies LLC manages $438.6M in 13F-reported U.S. long-equity assets across 147 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DBC (6.43%), ABVX (3.43%), RVMD (2.86%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 29 new positions and exited 38; 73 existing positions rose in reported value and 32 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$438.6M

Long-equity book

Holdings
147

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+29 / −38 / ↑73 / ↓32

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
DBC6.4% · 0%ABVX3.4% · -0%RVMD2.9% · -3%DFTX2.6% · +31%IMVT2.4% · +23%PRAX2.3% · +15%RLAY2.2% · +20%ALKS2.1% · +145%PCVX2.0% · +20%TNGX1.9% · +150%LQDA1.8% · -2%COGT1.7% · -4%GPCR1.6% · +6%ELVN1.6% · +89%AMLX1.6% · +10%SYRE1.6% · -47%LBRX1.6% · +22%CYTK1.5% · +33%CCCC1.4% · newTYRA1.3% · +41%ALMS1.3% · +77%PHVS1.3% · +64%TARS1.2% · +66%CMPS1.2% · +2%DNTH1.1% · +44%NRIX1.1% · -10%AXSM1.1% · -1%TVTX1.1% · +137%VERA1.0% · +53%NVDA1.0% · -3%GHRS1.0% · -26%PALI1.0% · +1%ARGX1.0% · -7%MAZE0.9% · +37%OCUL0.9% · -8%ORKA0.9% · -47%DYN0.9% · -6%EWTX0.8% · -1%MLTX0.8% · -3%INSM0.8% · +28%CLDX0.7% · -3%AMZN0.7% · -40%IVA0.7% · +35%TLN0.7% · +161%RLMD0.7% · newPTGX0.7% · -28%ERAS0.7% · -12%VRDN0.7% · +19%HPE0.6% · -34%MLYS0.5% · +84%GH0.5% · -34%AVTX0.5% · +109%JHX0.5% · +30%EYPT0.5% · -15%MTZ0.5% · +42%XENE0.5% · -28%RBC0.5% · +21%V0.5% · -16%ASMB0.5% · -2%STOK0.5% · -2%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 28.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People
Assets Under Management
$9.10B
Discretionary
$9.10B
Employees
80
Accounts
42
Address
200 CLARENDON STREET
50TH FLOOR
BOSTON, MA 02116
Phone
(617) 406-6500
Website
Name Title / Status Ownership Type
BOSTON, NICHOLAS, PATRICK ControlCHIEF COMPLIANCE OFFICERLess than 5%Individual
CHAN, LUKE, HENRY ControlPARTNERLess than 5%Individual
HIGHVISTA GP LLC ControlGENERAL PARTNERGeneral partnerDomestic Entity
HIGHVISTA MANAGEMENT PARTNERS LP ControlMEMBER75% or moreDomestic Entity
LANDEN, RONALD, ANTHONY ControlPARTNER & GENERAL COUNSELLess than 5%Individual
PAGE, CAROLINE, CHURCHILL ControlPARTNERLess than 5%Individual
PEROLD, ANDRE, FRANCOIS ControlPARTNERLess than 5%Individual
PEROLD, ANDRE, FRANCOIS ControlPARTNER25–50%Individual
PEROLD, ANDRE, FRANCOIS ControlMEMBER75% or moreIndividual
SCHORR, RAPHAEL, AVRAM ControlPARTNERLess than 5%Individual
SCHORR, RAPHAEL, AVRAM ControlPARTNER25–50%Individual

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

HighVista Strategies LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 INVESCO DB COMMDY INDX TRCK DBC 46138B103 $28.2M 6.43% 1,057,238 SH
2 ABIVAX SA ABVX 00370M103 $15.1M 3.43% 113,031 SH
3 REVOLUTION MEDICINES INC RVMD 76155X100 $12.5M 2.86% 66,983 SH
4 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $11.4M 2.60% 242,884 SH
5 IMMUNOVANT INC IMVT 45258J102 $10.7M 2.44% 277,873 SH
6 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $10.1M 2.31% 30,210 SH
7 RELAY THERAPEUTICS INC RLAY 75943R102 $9.5M 2.16% 506,235 SH
8 ALKERMES PLC ALKS G01767105 $9.4M 2.14% 179,256 SH
9 VAXCYTE INC PCVX 92243G108 $8.7M 1.98% 149,739 SH
10 TANGO THERAPEUTICS INC TNGX 87583X109 $8.1M 1.85% 260,070 SH
11 LIQUIDIA CORPORATION LQDA 53635D202 $7.8M 1.78% 97,896 SH
12 COGENT BIOSCIENCES INC COGT 19240Q201 $7.3M 1.67% 188,780 SH
13 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $7.0M 1.60% 130,784 SH
14 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $7.0M 1.60% 137,866 SH
15 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $6.9M 1.58% 386,080 SH
16 SPYRE THERAPEUTICS INC SYRE 00773J202 $6.9M 1.57% 77,807 SH
17 LB PHARMACEUTICALS INC LBRX 50180M108 $6.9M 1.57% 211,511 SH
18 CYTOKINETICS INC CYTK 23282W605 $6.6M 1.52% 78,003 SH
19 C4 THERAPEUTICS INC CCCC 12529R107 $6.3M 1.44% 1,348,136 SH
20 TYRA BIOSCIENCES INC TYRA 90240B106 $5.9M 1.35% 184,774 SH
21 ALUMIS INC ALMS 022307102 $5.6M 1.28% 199,968 SH
22 PHARVARIS N V PHVS N69605108 $5.5M 1.27% 160,494 SH
23 TARSUS PHARMACEUTICALS INC TARS 87650L103 $5.5M 1.25% 87,060 SH
24 COMPASS PATHWAYS PLC CMPS 20451W101 $5.3M 1.20% 371,120 SH
25 DIANTHUS THERAPEUTICS INC DNTH 252828108 $5.0M 1.14% 51,125 SH
26 NURIX THERAPEUTICS INC NRIX 67080M103 $4.9M 1.13% 203,739 SH
27 AXSOME THERAPEUTICS INC. AXSM 05464T104 $4.9M 1.13% 20,183 SH
28 TRAVERE THERAPEUTICS INC TVTX 89422G107 $4.9M 1.12% 86,233 SH
29 VERA THERAPEUTICS INC VERA 92337R101 $4.5M 1.04% 105,907 SH
30 NVIDIA CORPORATION NVDA 67066G104 $4.4M 0.99% 21,792 SH
31 GH RESEARCH PLC GHRS G3855L106 $4.3M 0.97% 158,770 SH
32 PALISADE BIO INC PALI 696389402 $4.2M 0.97% 2,030,927 SH
33 ARGENX SE ARGX 04016X101 $4.2M 0.96% 4,561 SH
34 MAZE THERAPEUTICS INC MAZE 578784100 $4.1M 0.93% 136,572 SH
35 OCULAR THERAPEUTIX INC OCUL 67576A100 $4.0M 0.91% 408,534 SH
36 ORUKA THERAPEUTICS INC ORKA 687604108 $4.0M 0.91% 41,902 SH
37 DYNE THERAPEUTICS INC DYN 26818M108 $3.8M 0.87% 171,961 SH
38 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $3.7M 0.84% 90,996 SH
39 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $3.7M 0.83% 187,946 SH
40 INSMED INC INSM 457669307 $3.3M 0.76% 31,256 SH
41 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $3.2M 0.74% 86,964 SH
42 AMAZON COM INC AMZN 023135106 $3.2M 0.73% 13,397 SH
43 INVENTIVA SA IVA 46124U107 $3.1M 0.72% 831,442 SH
44 TALEN ENERGY CORP TLN 87422Q109 $3.1M 0.71% 8,148 SH
45 RELMADA THERAPEUTICS INC RLMD 75955J402 $3.1M 0.70% 445,799 SH
46 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $3.0M 0.68% 24,460 SH
47 ERASCA INC ERAS 29479A108 $2.9M 0.67% 160,328 SH
48 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $2.9M 0.67% 159,885 SH
49 HEWLETT PACKARD ENTERPRISE C HPE 42824C109 $2.7M 0.61% 59,081 SH
50 MINERALYS THERAPEUTICS INC MLYS 603170101 $2.3M 0.53% 86,085 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $438.6M 147 0001172661-26-003470
2026-03-31 2026-05-15 $362.2M 156 0001172661-26-002079
2025-12-31 2026-02-17 $388.3M 145 0001172661-26-000882
2025-09-30 2025-11-14 $408.0M 148 0001172661-25-004799
Filer Information
Address
200 CLARENDON STREET, 50TH FLOOR
BOSTON, MA 02116
Phone
(617) 406-6500
Filing Manager
HighVista Strategies LLC
BOSTON, MA
Signatory
Nicholas Boston
Chief Compliance Officer